Melorask Pharma AB

Active
559349-2969Limited company (AB)Registered 2021BUNKEFLOSTRAND

Key figures

−1 kr−100,0%
Revenue 2025
-500 k0500 k1 m1,5 m2 m2022202320242025

Key figures

2025

Summary: Melorask Pharma AB

What kind of company is it?

Melorask Pharma AB (org. no. 559349-2969) is a limited company (AB). The company was registered in 2021 and has existed for 4 years. Registered seat: Bunkeflostrand. Industry according to Statistics Sweden: general primary medical practice activities (SNI 86211).

How is the company doing financially?

Net sales in financial year 2025 were −1 kr, down 100 % on the previous year (205 622 kr). Financial year 2025 ended with a loss of 88 700 kr. The company was profitable in 2 of the 5 reported financial years. According to the annual report, the company had no employees in financial year 2025. At the end of financial year 2025, total assets were 263 402 kr and equity 255 902 kr (equity ratio 97,2 %).

Where does the data come from and how up to date is it?

Company details and digitally filed annual reports come from the open data of the Swedish Companies Registration Office (Bolagsverket) and the industry code from Statistics Sweden (CC BY 2.5 SE); bolagsprofil.se updates them daily. The latest annual report is signed by one person. Data as of 2026-11-16. Changes, averages and ratios are calculated by bolagsprofil.se from open data and are not an official assessment.

Dividend

from the annual report
2025

No dividend was proposed.

History
20250 kr
20240 kr
20230 kr
2022195 250 kr
Summary of annual reports2021–2025
20212022202320242025
Sales revenue—1 538 7251 412 490205 622−1
Profit for the reporting year−11 687464 415191 260−129 135−88 700
Retained earnings of previous periods—————
Total assets17 313770 051544 810380 721263 402
Total liabilities4 000292 32371 07236 1197 500
Total equity13 313477 728473 738344 602255 902
Employees—2110
Proposed dividend—195 250000

A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.